Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye! - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2022

Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye!

Résumé

The Immune checkpoint blockers (ICB) have greatly improved clinical outcomes in multiple cancer types and are increasingly being used in earlier disease settings alone or in combination with other therapies. However, rare but life-threatening complications defined as immune-related adverse events (irAE) as ICI-induced myocarditis can occur, justifying close monitoring and specific management
Fichier principal
Vignette du fichier
2022 Maria et al., Immune checkpoint.pdf (143.2 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification

Dates et versions

hal-04013666 , version 1 (03-03-2023)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Alexandre T.J. Maria, Clement Delmas, Cyrille Coustal, Pascale Palassin, François Roubille. Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye!. European Journal of Cancer, 2022, 177, pp.194-196. ⟨10.1016/j.ejca.2022.09.028⟩. ⟨hal-04013666⟩
36 Consultations
8 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More